A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide

Trial Profile

A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms PASS MDS del5q
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 04 Nov 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2022.
    • 04 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2021.
    • 14 Jul 2015 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top